At Senti Biosciences, we’re powered by industry-leading management. Learn more about the $SNTI team here: https://t.co/2f9Nhkj5JO #CellTherapy #Oncology #AML

Behind every breakthrough is a patient, a family, a story. Our mission goes beyond science, it’s about giving hope to those fighting the toughest diseases. $SNTI #Oncology #Leukemia #CellTherapy

Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December https://t.co/TurnSJU79M $SNTI #CellTherapy #AML #Oncology

Senti Bio was featured in GEN’s “Biopharma Embraces Synthetic Biology” by Tiffany Yesavage, PhD — highlighting SENTI-202 and how our gene circuit technology is advancing next-generation programmable cell therapies. Read more: https://t.co/PyoPlSTBtS $SNTI #CellTherapy #AML

Founded on smart science. Driven by strong leadership. We’re relentlessly developing next-generation cancer therapies designed to outsmart the toughest diseases. $SNTI #CellTherapy #Leukemia #Oncology

At Senti Biosciences, we’re engineering cells with DNA-encoded programs that can sense, decide, and respond to disease, paving the way for a new era of smarter, more precise therapies. $SNTI #AML #Leukemia #Oncology

Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025 https://t.co/Z86MsRRqHk $SNTI #CellTherapy #AML #Oncology #AcuteMyeloidLeukemia

#DidYouKnow: Nearly 1 in 10 new cancer cases in the U.S. each year are blood cancers such as #Leukemia, #Lymphoma and #Myeloma. At $SNTI, we’re working to change outcomes with smarter, more precise therapies. #CellTherapy #AML #Oncology #AcuteMyeloidLeukemia

At Senti Bio, we’re committed to developing differentiated cancer therapies designed to outsmart the toughest diseases. $SNTI #CellTherapy #AML #Oncology #AcuteMyeloidLeukemia

Senti is pleased to be attending Chardan’s 9th Annual Genetic Medicines Conference in New York on October 21! Live webcast presentation on today, October 21st at 11:35 AM ET: https://t.co/R6ZT5ZsoA4 $SNTI #CellTherapy #AML #Oncology #AcuteMyeloidLeukemia

Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference on Tuesday, October 21st at 11:35 AM ET https://t.co/LLFf72WaqM $SNTI #CellTherapy #AML #Oncology #AcuteMyeloidLeukemia

Thank you to #BioJapan2025 for the opportunity to present in Yokohama! Our CEO & Co-Founder, Dr. Timothy Lu, shared insights on Senti’s synthetic biology platform and our progress advancing next-generation cell and gene therapies. $SNTI #CellTherapy #AcuteMyeloidLeukemia

Each year, about 20,800 people in the U.S. are diagnosed with #AML. Sadly, nearly 60% face relapse or death within the first year. At $SNTI Bio, we’re working to change this reality through innovative cell and gene therapies. #CellTherapy #AML #Oncology #AcuteMyeloidLeukemia

Senti Bio to Present at BioJapan on Thursday, October 9th at 11:30 AM JST https://t.co/Hjnloo2ZY1 $SNTI #CellTherapy #AML #CARNK

#InCaseYouMissedIt: $SNTI joined #VirtualInvestor, where Dr. Kanya Rajangam, Head of R&D, shared insights on the recommended Phase 2 dose of SENTI-202, our potential first-in-class CAR-NK therapy for #AML and other blood cancers. Watch the segment: https://t.co/HcRQkQ417K

We are excited to announce that Dr. Kanya Rajangam, President, Head of Research & Development, and Chief Medical Officer, will be presenting at the MedInvest Biotech & Pharma Investor Conference taking place September 24–25 in Palo Alto, CA. $SNTI #CellTherapy #AML #CARNK

Senti Bio to Present at the MedInvest Biotech & Pharma Conference on Wednesday, September 24th at 9:55 AM PT https://t.co/ryryZUpWuo $SNTI #CellTherapy #AML #CARNK #AcuteMyeloidLeukemia

Tomorrow at 9:05 AM PT, Vice President of Research Brian Garrison will present on Next-Generation Personalized Cell Therapy Engineering Innovations at Advanced Therapies Xchange in San Francisco, CA. $SNTI #AML #CellTherapy

Halfway through Blood Cancer Awareness Month, we’re reminded that behind every statistic is a person — a patient, a caregiver, a loved one — facing the challenges of blood cancer. Let’s continue to raise awareness, share knowledge and stand together in hope. $SNTI #CellTherapy

If you missed our CEO, Tim Lu, at the H.C. Wainwright 27th Annual Global Investment Conference, don’t worry — you can watch the full presentation now! 🎥 Replay available here: https://t.co/QwmYmwmNzN $SNTI #CellTherapy #AML #CARNK #AcuteMyeloidLeukemia